OR WAIT null SECS
March 02, 2017
The new ISPE Containment Manual is a summary of the process involved in the manufacture of highly active or highly hazardous pharmaceutical substances.
March 01, 2017
The article reviews strategies for firms with or without existing in-house capacities and the pros and cons for outsourcing bio/pharmaceutical development and manufacturing.
February 28, 2017
The agency cited the company’s Kansas facility with CGMP violations similar to problems found at other Hospira facilities.
February 27, 2017
Avella issued a nationwide recall of sterile products produced at the Advanced Pharma Houston location due to inaccurate labeling.
The company is voluntarily recalling one lot of Edex due to a lack of container closure integrity.
February 16, 2017
FDA sent a warning letter to Sato Pharmaceutical Co., Ltd. after inspectors found deviations in the facility’s aseptic processes.
February 15, 2017
The agency sent a warning letter to Resonance Laboratories Pvt. Ltd. after an inspection found possible contamination problems.
The company has voluntarily recalled all lots of of human chorionic gonadotropin because of a lack of sterility assurance.
February 02, 2017
Susan Schniepp, distinguished fellow at Regulatory Compliance Associates, discusses how to ensure sterility when manufacturing small-scale parenteral batches.
January 25, 2017
The agency finds repeated CGMP violations at Porton Biopharma, Limited.